EPS for AmpliPhi Biosciences Corporation (APHB) Expected At $-0.36

March 16, 2018 - By Nellie Frank

 EPS for AmpliPhi Biosciences Corporation (APHB) Expected At $ 0.36

Analysts expect AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) to report $-0.36 EPS on March, 26.They anticipate $2.84 EPS change or 88.75 % from last quarter’s $-3.2 EPS. After having $-0.09 EPS previously, AmpliPhi Biosciences Corporation’s analysts see 300.00 % EPS growth. The stock decreased 3.14% or $0.05 during the last trading session, reaching $1.54. About 195,228 shares traded. AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) has declined 94.86% since March 16, 2017 and is downtrending. It has underperformed by 111.56% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $14.63 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: